Gillian Atkinson, United States
STEADFAST Study Update: A Phase 1/2 Clinical Trial of Regulatory T Cells Expressing a Chimeric Antigen Receptor Directed Towards HLA-A2 in Renal Transplantation

Idelberto Badell, United States
Every 2-Month Belatacept Maintenance Therapy in Kidney Transplant Recipients: 5-Year Follow-Up of a Randomized, Noninferiority Trial

Sandy Honda, United States
Clinical Validation of a Novel Rapid Test for Point-of-Care Tacrolimus Monitoring in Kidney Transplant Recipients

Idelberto Badell, United States
Late Abatacept Conversion in Kidney Transplant Recipients Receiving Belatacept: A Prospective, Randomized Controlled Noninferiority Trial

Ashley Vo, United States
Daratumumab (Anti-CD38) Desensitization in HLA Sensitized Patients: Long-Term Follow-Up

Ali Abbasi, United States
Mechanistic Insights Underlying Persistent Beneficial Impact on Kidney Function of CCR5 Blockade Following Treatment Discontinuation

Maria Meneghini, Spain
Histological Reversal of Refractory ABMR with Daratumumab in Kidney Transplant Patients

Eliezer Katz, United States
Tegoprubart, an Anti-CD40L Antibody, for the Prevention of Rejection in Kidney Transplantation: An Ongoing Phase 1B Study